InfectoPharm Invests in AudioCure to Advance Innovative Hearing Loss Therapy
13.2.2025 15:03:00 CET | Business Wire | Press release
Drug candidate AC102 in the clinical phase
There is currently no drug approved worldwide for the treatment of sudden hearing loss. However, preclinical and clinical phase-1-studies with the innovative drug candidate AC102 have been promising. AudioCure Pharma, a Berlin-based start-up supported by investors, is driving forward research and development. Now, InfectoPharm, a successful medium-sized company, is joining as a new and essential competence partner.The Heppenheim-based ENT specialist is leading the new round of financing and is strengthening the existing group of investors, which includes main investor MED-EL and seed investor High-Tech Gründerfonds (HTGF). The main goal of the collaboration is to successfully advance the clinical development of AC102, a drug for sudden hearing loss.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213622345/en/
Investors in the current financing round with AudioCure Management. From left to right: Philipp Zöller (CEO InfectoPharm), Prof Hans Rommelspacher (founder AudioCure), Dr Reimar Schlingensiepen (CEO AudioCure), Dr Ingeborg Hochmair (CEO MED-EL) and Dr Christian Kannemeier (Senior Investment Manager HTGF). Copyright: AudioCure.
The investors are not only providing AudioCure with financial support for the development of new drugs, but are also expanding its knowledge base with their respective scientific and commercial expertise. MED-EL Medical-Electronics and InfectoPharm Arzneimittel are contributing their extensive expertise gained from over 30 years in the ENT field. Dr Reimar Schlingensiepen, CEO of AudioCure, is delighted: ‘AudioCure and its partners complement each other perfectly. Together, we can advance our research and development activities even further and develop innovative active ingredients. We are also pleased to now have InfectoPharm's many years of experience in the pharmaceutical industry on board.’
The additional funds will mainly be used for the further development of the drug candidate AC102. This has already been successfully tested for tolerability and safety in humans and is currently being investigated in a Europe-wide phase-2-study for its efficacy in sudden hearing loss patients. In preclinical models of hearing loss, AC102 was able to restore hearing almost completely, exceeding the efficacy of conventional corticosteroid therapies. Philipp Zöller, managing partner of InfectoPharm Arzneimittel und Consilium GmbH, comments: ‘As a specialist in pharmaceutical products for ear, nose and throat conditions, we are very familiar with the difficult situation of sudden hearing loss patients. We are therefore delighted to be able to support the development of a potentially groundbreaking drug like AC102, both financially and with our expertise, as part of the AudioCure investor team.’
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213622345/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Announces Results of the Annual General Meeting2.4.2026 16:49:00 CEST | Press release
SES (the “Company”) held the Annual General Meeting (“AGM”) of Shareholders today in Betzdorf, Luxembourg. Following the recommendations made by the Board of Directors of SES, the shareholders have voted in favor of all resolutions, including the Company’s 2025 annual accounts and the proposed annual dividend of EUR 0.50 per A-share (EUR 0.20 per B-share). The total dividend amount comprises the interim dividend of EUR 0.25 per A-share (EUR 0.10 per B-share), which has already been paid to shareholders on October 16, 2025. The final dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) will be paid to shareholders on April 16, 2026. “I would like to sincerely thank our shareholders for their active engagement, visionary support and continued confidence in SES’ strategy,” said Adel Al-Saleh, CEO of SES. “The outcomes of today’s AGM underscore our shared commitment to a bold multi-orbit approach, with Medium Earth Orbit as the strategic backbone of a dynamically evolving global interco
Andersen Consulting styrker sine kompetencer med tilføjelsen af Lukkap2.4.2026 16:31:00 CEST | Pressemeddelelse
Andersen Consulting tilføjer samarbejdspartneren Lukkap, et konsulenthus med fokus på oplevelsesdrevne kompetencer, der er tilpasset kundernes skiftende behov inden for transformation af medarbejdere, kunder og det digitale område. Lukkap, der blev stiftet i 2009 og har hovedsæde i Spanien, leverer integrerede løsninger, der hjælper organisationer med at transformere, hvordan de betjener kunder, engagerer medarbejdere og frigør værdi gennem adfærdsindsigt og dataanalyse. Virksomhedens tværfaglige tilgang spænder over nytænkning af kunderejsen, effektive programmer for medarbejderoplevelser, talent- og ledelsesudvikling, prædiktiv analyse samt omfattende outplacement- og transitionsydelser. Lukkap arbejder på tværs af sektorer — herunder sundhedsvæsen, medicinalindustri, forbrugsgoder, detailhandel, finans og bankvæsen — for at opbygge menneskecentrerede strategier, der skaber målbare forretningsresultater. "Ved at kombinere vores erfaringsdrevne metode med Andersen Consultings globale
Forrester: Three Years Into GenAI, Enterprises Are Still Chasing Its True Transformative Value2.4.2026 16:00:00 CEST | Press release
Low AI fluency, uneven adoption, and marginal productivity gains are limiting enterprise-scale impact According to Forrester’s (Nasdaq: FORR) latest report, Accelerate Your AI Voyage, most enterprises are struggling to turn growing AI adoption and investment into measurable business impact. One of the key factors holding businesses back is low artificial intelligence quotient (AIQ) — Forrester’s measure of AI aptitude — with many employees lacking a clear understanding of how to use AI. Other barriers include an overemphasis on productivity-focused use cases, difficulty measuring impact, and siloed adoption within individual functions. While these challenges can leave firms frozen in doubt or indecision, the wait-and-see approach to AI adoption is no longer viable. To unlock AI’s full potential, organizations need to focus on four key areas: Define the business outcomes and success metrics for what they want AI to achieve; identify specific use cases for AI deployment aligned to those
The LYCRA Company Announces Strategic Partnership on Renewable LYCRA® Fiber2.4.2026 15:00:00 CEST | Press release
Agreement with Texhong Advances Sustainable Fiber Applications The LYCRA Company, a global leader in innovative and sustainable fiber solutions for the apparel and personal care industries, today announced the signing of a strategic partnership agreement with Texhong International Group Limited (“Texhong”), one of the world’s largest suppliers of core-spun cotton textiles. Under the agreement, Texhong will exclusively partner with The LYCRA Company to bring Renewable LYCRA® fiber made with 30 percent plant-based content* to China’s core-spun yarn sector. This collaboration aims to accelerate the adoption of bio-derived spandex across the global apparel and textile industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260402505834/en/ The LYCRA Company announced a strategic partnership with Texhong International Group for renewable LYCRA® fiber. Pictured at the signing ceremony held in Shanghai (left to right): Jason Wang,
Brightfin Unifies Brand Following Proven Optics Merger, Delivering a New Standard for Technology Cost Optimization2.4.2026 15:00:00 CEST | Press release
New identity reflects expanded vision to help CIOs “See Clearly. Spend Better.” Brightfin today announced that, following its merger with Proven Optics, the combined company will operate under a single brand: Brightfin. The unified company brings together deep expertise in Technology Expense Management (TEM) and IT Financial Management (ITFM) to help organizations better understand, manage, and reduce total technology spend. Technology spending will exceed $6 Trillion this year, and for most organizations, it remains one of the least understood. CIOs can tell you what they’re spending. Far fewer can tell you whether it’s working. “Over the past several months, we’ve brought these two businesses together around a shared purpose: help enterprise businesses better understand and optimize their technology spend,” said Joel Martins, CEO of Brightfin. “What we are seeing now is a shift. Visibility alone isn’t enough. Teams need to be able to act, tied to real financial outcomes. See Clearly.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom